The Ledger

RMD

Resmed IncHealth Careinsider_universe

Last close $201.73Jun 28, 2026

Day +0.72%

Currently held

Agent 8 — Dip Buyer (Peer-Aware)long
7 sh @ $190.57 · stop $175.32
+$57.12 unrealized
Agent 4 — Dip Buyer (Frozen)long
5 sh @ $186.35 · stop $171.44
+$61.90 unrealized

Everything we've seen

·Jun 29, 2:19 PMstreamnews
Are Options Traders Betting on a Big Move in ResMed Stock?
Investors need to pay close attention to RMD stock based on the movements in the options market lately.
❖Jun 29, 11:22 AMnewsvia finnhub
Are Options Traders Betting on a Big Move in ResMed Stock?
Investors need to pay close attention to RMD stock based on the movements in the options market lately.
!Jun 29, 9:51 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 29, 7:06 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 12:49 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 11:51 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 10:48 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 10:35 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 10:21 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 9:50 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 9:35 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 9:17 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 26, 7:03 AMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 5:47 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 5:31 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 5:16 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 5:06 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 4:47 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 4:32 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 4:21 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 3:47 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 3:33 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 3:17 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 2:48 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 2:35 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 2:20 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 1:47 PMsignal
Agent 6 — Options Momentum — insufficient_capital
!Jun 25, 1:35 PMsignal
Agent 6 — Options Momentum — insufficient_capital
❖Jun 25, 8:40 AMnewsvia finnhub
Is ResMed Inc. (RMD) Stock Still a Long-Term Winner as OSA Market Expansion Continues?
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. ResMed Inc. (NYSE:RMD) is among the best healthcare stocks. TheFly reported on June 22 that KeyBanc adjusted its price target for RMD to $266 from $290 while maintaining an Overweight rating on the shares. The firm noted that […]
?Jun 24, 10:15 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
RMD is up ~3% intraday, which represents meaningful institutional flow and conviction. The macro backdrop is modestly supportive — T10YIE printing 2.0σ below trend indicates compressed inflation expectations, which favors long-duration sensitive sectors and medical device companies like ResMed that benefit from lower discount rates. The single headline references RMD as 'oversold and primed to rebound,' which is a mild positive catalyst consistent with a mean-reversion bid. However, several factors temper enthusiasm: (1) 330 minutes remaining is actually a large portion of the trading day, meaning there is ample time for a fade — counterintuitively, more time introduces more uncertainty here rather than providing room to run, as the move has already largely occurred; (2) no strong fundamental catalyst (earnings, guidance raise, FDA approval) is evident to sustain the move beyond initial buying; (3) at ~3% up, RMD is approaching a natural short-term resistance zone where profit-taking could emerge. The absence of a hard reversal signal and the supportive macro context keep probability above 0.5, but this is a borderline read — standard momentum continuation with no strong amplifier or fade signal.
!Jun 24, 10:15 AMsignalseverity 0.03
Agent 7 — Day Trader — day_trade_skipped
RMD is up ~3% intraday, which represents meaningful institutional flow and conviction. The macro backdrop is modestly supportive — T10YIE printing 2.0σ below trend indicates compressed inflation expectations, which favors long-duration sensitive sectors and medical device companies like ResMed that benefit from lower discount rates. The single headline references RMD as 'oversold and primed to rebound,' which is a mild positive catalyst consistent with a mean-reversion bid. However, several factors temper enthusiasm: (1) 330 minutes remaining is actually a large portion of the trading day, meaning there is ample time for a fade — counterintuitively, more time introduces more uncertainty here rather than providing room to run, as the move has already largely occurred; (2) no strong fundamental catalyst (earnings, guidance raise, FDA approval) is evident to sustain the move beyond initial buying; (3) at ~3% up, RMD is approaching a natural short-term resistance zone where profit-taking could emerge. The absence of a hard reversal signal and the supportive macro context keep probability above 0.5, but this is a borderline read — standard momentum continuation with no strong amplifier or fade signal.
❖Jun 24, 9:30 AMnewsvia finnhub
[Latest] Global Neonatal Intensive Care Respiratory Devices Market Size/Share Worth USD 5.7 Billion by 2035 at a 10.5% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Healthcare Foresights, the demand analysis of Global Neonatal Intensive Care Respiratory Devices Market size & share revenue was valued at approximately USD 2.1 Billion in 2025 and is expected to reach USD 2.3 Billion in 2026 and is expected to reach around USD 5.7 Billion by 2035, at a CAGR of 10.5% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are Inspirat
❖Jun 24, 6:16 AMnewsvia finnhub
1 Oversold Stock Primed to Rebound and 2 We Find Risky
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether they’re witnessing fire sales or falling knives.
?Jun 23, 10:45 AMdecisionconsidered
Agent 7 — Day Trader — analyze: fail
Claude analysis failed: Anthropic 529: {"type":"error","error":{"type":"overloaded_error","message":"Overloaded"},"request_id":"req_011CcLNVb6MjwJsmuhkvAyby"}
!Jun 23, 10:45 AMsignal
Agent 7 — Day Trader — analyze_failed
?Jun 23, 8:51 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $19.16 cash available; close=$188.45.
?Jun 23, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $19.16 cash available; close=$188.45.
!Jun 23, 7:03 AMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $12.30 cash available; close=$188.45.
?Jun 22, 7:21 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $12.30 cash available; close=$188.45.
!Jun 22, 7:21 PMsignal
Agent 5 — Dip Buyer (Evolving) — insufficient_capital
Wanted to buy but only $1.92 cash available; close=$188.63.
?Jun 22, 7:05 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.92 cash available; close=$188.63.
❖Jun 22, 5:13 AMnewsvia finnhub
Keybanc Maintains Overweight on ResMed, Lowers Price Target to $266
Keybanc analyst Justin Patterson maintains ResMed (NYSE:RMD) with a Overweight and lowers the price target from $290 to $266.
❖Jun 19, 2:00 PMnewsvia finnhub
Here’s How Much You Would Have Made Owning ResMed Stock In The Last 20 Years
ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 1.89% on an annualized basis producing an average annual return of 11.28%. Currently, ResMed has a market capitalization of $27.48 billion. Buying
?Jun 18, 6:04 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.52 cash available; close=$188.61.
❖Jun 18, 11:17 AMnewsvia finnhub
Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos
Check out the companies making headlines yesterday:
?Jun 18, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $10.13 cash available; close=$186.29.
❖Jun 18, 6:50 AMnewsvia finnhub
Morgan Stanley Downgrades ResMed (RMD)
❖Jun 18, 6:31 AMnewsvia finnhub
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday
Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax target increased, Sezzle target up, Biogen target raised, Progressive target cut.
?Jun 17, 6:06 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $11.35 cash available; close=$186.35.
✓Jun 17, 6:05 PMdecisionacted
Agent 4 — Dip Buyer (Frozen) — decide: buy
ResMed (RMD) is a high-quality medical device company with strong fundamentals in the sleep apnea and respiratory care space, and the 12.7% pullback from the 30-day high does not appear tied to any company-specific deterioration — no negative SEC filings, earnings misses, or guidance cuts are evident in the available evidence. The drop appears to be driven by broader healthcare sector weakness (sector-wide retreat noted in recent headlines) and a macro environment where a flattening yield curve (T10Y2Y at 2.3σ below trend) is pressuring growth-oriented healthcare names. RMD's durable competitive moat, recurring revenue from connected device subscriptions, and consistent profitability make it a credible bounce candidate.
❖Jun 17, 4:51 PMnewsvia finnhub
Why ResMed (RMD) Shares Are Falling Today
Shares of medical device company ResMed (NYSE:RMD) fell 4.5% in the afternoon session after Morgan Stanley downgraded the stock to Equalweight from Overweight and lowered its price target.
❖Jun 17, 4:35 PMnewsvia finnhub
Stocks Retreat as Fed Signals Possible Higher Interest Rates
The S&P 500 Index ($SPX ) (SPY ) on Wednesday closed down -1.21%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.98%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.99%. June E-mini S&P futures (ESM26 ) fell -1.19%, and June E-mini Nasdaq futures...
❖Jun 17, 3:38 PMnewsvia finnhub
Sector Update: Healthcare Stocks Retreat Late Afternoon
Healthcare stocks declined late Wednesday afternoon, with the NYSE Healthcare Index falling 1.3% and
❖Jun 17, 3:05 PMnewsvia finnhub
Stay informed with the top movers within the S&P500 index on Wednesday.
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Wednesday. Discover which stocks are leading as top gainers and losers in today's session.
❖Jun 17, 11:22 AMnewsvia finnhub
Stocks Mixed Ahead of FOMC Meeting Results
The S&P 500 Index ($SPX ) (SPY ) today is down -0.15%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.30%. June E-mini S&P futures (ESM26 ) are down -0.17%, and June E-mini Nasdaq futures...
❖Jun 17, 10:09 AMnewsvia finnhub
Stocks Supported by Chip Stock Strength and Strong US Retail Sales
The S&P 500 Index ($SPX ) (SPY ) today is up +0.23%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.26%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.74%. June E-mini S&P futures (ESM26 ) are up +0.19%, and June E-mini Nasdaq futures...
❖Jun 17, 9:47 AMnewsvia finnhub
Lyft upgraded, Leidos downgraded: Wall Street's top analyst calls
Lyft upgraded, Leidos downgraded: Wall Street's top analyst calls
?Jun 17, 9:46 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
RMD is down ~1.51% today with no attributable headline catalyst. The move is modest — below the 2-5% threshold that signals strong conviction flow — so it likely reflects broad market drift or sector rotation rather than a name-specific thesis. The macro context (T10Y2Y at 0.38, 2.3σ below trend) is a flattening/low-spread environment that tends to favor defensives like RMD rather than pressure them, which slightly cuts against continuation of the downside. With 360 minutes remaining there is ample time for either continuation or reversal, but the absence of a catalyst and the macro backdrop that isn't hostile to this sector limits conviction on further downside. No reversal pattern or volume signal is explicitly evident, and the system's bounded risk profile justifies taking the borderline read, but the macro tilt toward defensives prevents a higher continuation probability. Assigning 0.50 — minimum threshold for a position — reflecting neutral evidence with a slight lean toward fade given defensive sector macro support.
❖Jun 17, 6:37 AMnewsvia finnhub
Nasdaq Futures Climb as Chip Stocks Rebound Ahead of First Fed Decision Under Warsh
June Nasdaq 100 E-Mini futures (NQM26) are up +0.54% this morning, signaling a rebound from yesterday’s selloff, while investors await the first Federal Reserve rate decision under Kevin Warsh.
❖Jun 17, 5:13 AMnewsvia finnhub
This ResMed Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday
Wall Street analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrades, initiations. See opinions on EFC stock.
❖Jun 17, 5:05 AMnewsvia finnhub
Delta Air Lines To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed outlook on top names. Baird raised prices for Ryder System and J B Hunt, Needham for Glaukos, B of A for CSX, Morgan Stanley for Charles River, and Bernstein for Delta Air.
❖Jun 17, 4:42 AMnewsvia finnhub
Morgan Stanley Downgrades ResMed to Equal-Weight, Lowers Price Target to $230
Morgan Stanley analyst David Bailey downgrades ResMed (NYSE:RMD) from Overweight to Equal-Weight and lowers the price target from $286 to $230.
❖Jun 15, 12:17 AMnewsvia finnhub
ResMed (RMD) Stock Valuation Check After Mixed Returns And Undervaluation Signals
Recent performance snapshot ResMed (RMD) has drawn investor attention after a period of mixed share performance, with the stock up about 1% over the past day but down over the past week, month, past 3 months and year. That backdrop makes the current fundamentals worth a closer look, including revenue of US$5.54b, net income of US$1.52b and a market value around US$28.13b, alongside a mid range value score of 5. See our latest analysis for ResMed. The latest 1 day share price return of 1.24%...
❖Jun 12, 2:45 PMnewsvia finnhub
Dividend Champion, Contender, And Challenger Highlights: Week Of June 14
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Read the full analysis here.
?Jun 12, 7:04 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $9.47 cash available; close=$192.39.
?Jun 11, 6:04 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ResMed (RMD) is a fundamentally strong medical device company with a dominant position in sleep apnea and respiratory care, historically characterized by durable revenue growth, high margins, and strong free cash flow. The 13.2% pullback from the 30-day high occurs in a context with no available news or SEC filings to explain the drop, suggesting this is likely macro/sector rotation rather than company-specific deterioration. The flat-to-modestly-positive yield curve environment (T10Y2Y at 0.41, below trend) may be creating mild headwinds for growth-oriented healthcare names, but RMD's defensive earnings profile provides some insulation.
❖Jun 11, 11:25 AMnewsvia finnhub
Is ResMed Inc. (RMD) A Good Stock To Buy Now?
Is RMD a good stock to buy? We came across a bullish thesis on ResMed Inc. on r/investing_discussion by Variant_Invest. In this article, we will summarize the bulls’ thesis on RMD. ResMed Inc.’s share was trading at $196.94 as of June 9th. RMD’s trailing and forward P/E were 18.99 and 16.61 respectively according to Yahoo Finance. ResMed […]
❖Jun 11, 9:20 AMnewsvia finnhub
Is ResMed Stock Underperforming the Dow?
While ResMed has underperformed relative to the Dow over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.
?Jun 11, 7:04 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $18.65 cash available; close=$193.57.
❖Jun 11, 3:05 AMnewsvia finnhub
ResMed: GLP-1 Threats Are Overstated
ResMed's GLP-1 concerns are overstated, and though a portion of market share will be lost, the remaining portion will be more beneficial to profitability. Learn more about RMD stock here.
?Jun 10, 8:06 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ResMed (RMD) is a fundamentally strong medical device company with a dominant position in sleep apnea and respiratory care, historically characterized by durable revenue growth, high margins, and strong free cash flow. The 13.2% pullback from the 30-day high occurs in a context with no available news or SEC filings to explain the drop, suggesting this is likely macro/sector rotation rather than company-specific deterioration. The flat-to-modestly-positive yield curve environment (T10Y2Y at 0.41, below trend) may be creating mild headwinds for growth-oriented healthcare names, but RMD's defensive earnings profile provides some insulation.
?Jun 10, 7:40 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$196.94.
?Jun 10, 7:31 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$196.94.
?Jun 10, 7:21 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$196.94.
?Jun 9, 6:06 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$196.95.
?Jun 9, 6:05 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ResMed (RMD) is a fundamentally strong medical device company with a dominant position in sleep apnea and respiratory care, historically characterized by durable revenue growth, high margins, and strong free cash flow. The 13.2% pullback from the 30-day high occurs in a context with no available news or SEC filings to explain the drop, suggesting this is likely macro/sector rotation rather than company-specific deterioration. The flat-to-modestly-positive yield curve environment (T10Y2Y at 0.41, below trend) may be creating mild headwinds for growth-oriented healthcare names, but RMD's defensive earnings profile provides some insulation.
❖Jun 9, 8:55 AMnewsvia finnhub
Is This the Right Time to Retain Resmed Stock in Your Portfolio?
RMD gains from acquisition-led Residential Care Software growth, mask innovation and strong finances but faces macro and competitive pressures.
?Jun 9, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$193.14.
?Jun 8, 6:26 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ResMed (RMD) is a fundamentally strong medical device company with a dominant position in sleep apnea and respiratory care, historically characterized by durable revenue growth, high margins, and strong free cash flow. The 13.2% pullback from the 30-day high occurs in a context with no available news or SEC filings to explain the drop, suggesting this is likely macro/sector rotation rather than company-specific deterioration. The flat-to-modestly-positive yield curve environment (T10Y2Y at 0.41, below trend) may be creating mild headwinds for growth-oriented healthcare names, but RMD's defensive earnings profile provides some insulation.
?Jun 8, 6:06 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ResMed (RMD) is a fundamentally strong medical device company with a dominant position in sleep apnea and respiratory care, historically characterized by durable revenue growth, high margins, and strong free cash flow. The 13.2% pullback from the 30-day high occurs in a context with no available news or SEC filings to explain the drop, suggesting this is likely macro/sector rotation rather than company-specific deterioration. The flat-to-modestly-positive yield curve environment (T10Y2Y at 0.41, below trend) may be creating mild headwinds for growth-oriented healthcare names, but RMD's defensive earnings profile provides some insulation.
?Jun 8, 6:05 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$193.15.
?Jun 8, 12:31 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.00 cash available; close=$193.85.
?Jun 8, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $5.82 cash available; close=$196.04.
❖Jun 8, 12:51 AMnewsvia finnhub
Top 50 High-Quality Dividend Growth Stocks For June 2026
A curated universe of 50 high-quality dividend growth stocks identifies attractive entry points based on valuation and forward return potential. Check out the list here.
?Jun 7, 1:13 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.16 cash available; close=$196.04.
❖Jun 5, 5:24 PMnewsvia finnhub
ResMed (RMD) Acquires Noctrix Health to Expand Sleep Disorder Portfolio
ResMed Inc. (NYSE:RMD) is one of the most undervalued large cap stocks to buy according to analysts. On June 1, ResMed finalized its acquisition of Noctrix Health, a medical device company known for developing non-pharmacologic wearable therapeutics. This strategic move expands ResMed’s clinical sleep health portfolio into the treatment of Restless Legs Syndrome/RLS, which is […]
❖Jun 5, 3:15 PMnewsvia finnhub
ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow
2026-06-05. The following slide deck was published by ResMed Inc.
?Jun 5, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.52 cash available; close=$194.32.
?Jun 4, 6:04 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $0.53 cash available; close=$194.32.
?Jun 4, 6:03 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ResMed (RMD) is a fundamentally strong medical device company with a dominant position in sleep apnea and respiratory care, historically characterized by durable revenue growth, high margins, and strong free cash flow. The 13.2% pullback from the 30-day high occurs in a context with no available news or SEC filings to explain the drop, suggesting this is likely macro/sector rotation rather than company-specific deterioration. The flat-to-modestly-positive yield curve environment (T10Y2Y at 0.41, below trend) may be creating mild headwinds for growth-oriented healthcare names, but RMD's defensive earnings profile provides some insulation.
❖Jun 4, 3:23 PMnewsvia finnhub
ResMed Inc. (RMD) Presents At 46th Annual William Blair Growth Stock Conference Transcript
ResMed (RMD) outlines growth catalysts in sleep & breathing health: AI, wearables, GLP-1 tailwinds, COPD, and Noctrix RLS dealâread key takeaways now.
❖Jun 4, 7:17 AMnewsvia finnhub
ResMed completes $340m Noctrix Health acquisition
Noctrix Health’s lead product, Nidra, targets the peroneal nerves to address the symptoms of restless leg syndrome.
?Jun 4, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $43.66 cash available; close=$186.46.
▣Jun 3, 8:00 PMjournalstop
Agent 6 — Options Momentum closed long 100 @ $5.29 (-$221.79)
Stop: premium $5.29 ≤ trailing floor $8.41 (peak $11.21 × 0.75)
?Jun 3, 6:05 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.84 cash available; close=$186.46.
❖Jun 3, 1:43 PMnewsvia finnhub
3 Big Reasons RMD Should Be On Your Watchlist
ResMed’s stock price has taken a beating over the past six months, shedding 26.3% of its value and falling to $185.29 per share. This may have investors wondering how to approach the situation.
?Jun 3, 10:37 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ResMed (RMD) is a high-quality medical device company with a dominant position in sleep apnea and respiratory care, a strong recurring revenue base from device consumables and cloud-connected software, and historically solid free cash flow generation. The 18.7% drawdown from the 30-day high occurs in a news vacuum — no recent headlines or SEC filings are available to explain the drop, which suggests the move may be driven by sector rotation, broader market risk-off, or GLP-1 obesity drug overhang fears (a recurring narrative for RMD) rather than company-specific deterioration. The macro backdrop shows a T10Y3M spread elevated at +0.76 (1.6σ above trend), which modestly pressures growth/healthcare multiples but is not specifically damaging to RMD's defensive recurring-revenue model.
?Jun 3, 10:36 AMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ResMed (RMD) is a high-quality medical device company with a dominant position in sleep apnea and respiratory care, a strong recurring revenue base from device consumables and cloud-connected software, and historically solid free cash flow generation. The 18.7% drawdown from the 30-day high occurs in a news vacuum — no recent headlines or SEC filings are available to explain the drop, which suggests the move may be driven by sector rotation, broader market risk-off, or GLP-1 obesity drug overhang fears (a recurring narrative for RMD) rather than company-specific deterioration. The macro backdrop shows a T10Y3M spread elevated at +0.76 (1.6σ above trend), which modestly pressures growth/healthcare multiples but is not specifically damaging to RMD's defensive recurring-revenue model.
?Jun 3, 9:00 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
RMD is down ~1.94% today, a meaningful but not extreme move. The primary catalyst appears to be the $340M acquisition of Noctrix Health announced this morning — M&A spend often weighs on acquirer shares intraday as investors price in capital deployment and execution risk, which provides a fundamental rationale for the selling pressure to persist. The William Blair conference presentation is largely neutral. Macro context (T10Y2Y at 2σ below trend, mild bear-flattening) is modestly unfavorable for growth/medical device names like RMD, providing a soft tailwind to the downside. With 405 minutes remaining (well over 6 hours), there is ample time for the move to extend. However, the acquisition price of $340M is relatively modest for a company of RMD's size (~$25B market cap, ~1.4% of market cap), which may limit the downside overhang — sophisticated buyers may step in on this dip once the initial reaction fades. No reversal pattern is evident from the data provided. On balance, slight continuation probability favoring the existing downtrend, but not a high-conviction setup — rated just above the 0.5 threshold given the M&A-driven selling catalyst, ample time remaining, and mildly unfavorable macro backdrop.
❖Jun 3, 8:14 AMnewsvia finnhub
Is It Time To Reassess ResMed (RMD) After A 25% Share Price Slide?
If you are wondering whether ResMed at around US$182.82 is pricing in too much optimism or not enough, you are in the right place to assess what that tag might actually represent. The stock has had a weaker run recently, with the share price down 12.1% over the past week, 10.8% over the past month, and 25.3% year to date, the same decline as over the past year. These moves sit against a backdrop of ongoing interest in sleep and respiratory care solutions and broader discussion around how...
❖Jun 3, 7:40 AMnewsvia finnhub
Angelini Ventures Marks First Portfolio Company Exit as ResMed Acquires Noctrix Health for $340 million
Noctrix Health acquisition validates Angelini Ventures’ strategy of investing in innovative healthcare companies addressing significant unmet medical needs and advancing connected health Rome, Italy, 3rd June 2026 – Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been acquired by ResMed (NYSE: RMD), a global leader in sleep health a
✓Jun 3, 7:02 AMdecisionacted
Agent 5 — Dip Buyer (Evolving) — decide: buy
Wanted to buy but only $8.58 cash available; close=$182.83.
❖Jun 3, 3:45 AMnewsvia finnhub
ResMed Acquires Sleep-Related Wearables Developer Noctrix Health From Angelini Industries For $340M
Angelini Ventures, the corporate venture firm of Angelini Industries focused on investing in companies developing innovative solutions in BioTech and HealthTech, announces that portfolio company Noctrix Health has been
❖Jun 3, 12:04 AMnewsvia finnhub
ResMed Inc. (RMD) Presents at 46th Annual William Blair Growth Stock Conference Prepared Remarks Transcript
ResMed Inc. (RMD) 46th Annual William Blair Growth Stock Conference June 2, 2026 5:40 PM EDTCompany ParticipantsMichael Farrell - CEO &...
?Jun 2, 6:04 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $8.58 cash available; close=$182.83.
?Jun 2, 9:56 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
RMD is down ~2% intraday with no headline catalyst visible, suggesting this is likely flow/technical driven rather than a news shock. The macro context shows a flattening yield curve (T10Y2Y at 2-sigma below trend), which tends to favor defensives — RMD as a medical device company (sleep/respiratory) has some defensive characteristics, meaning this macro backdrop is mildly at odds with continued selling pressure. However, a ~2% move represents real institutional conviction on the sell side, and without a reversal signal or catalyst to flip sentiment, the default lean is mild continuation. With 350 minutes remaining (effectively a full remaining session), there is ample time for the move to extend. No news absence is not disqualifying per framework. The yield curve context provides a mild headwind to further downside but not strong enough to call a reversal. Overall: modest continuation probability with the existing down move.
?Jun 2, 7:01 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $1.04 cash available; close=$186.44.
❖Jun 2, 2:30 AMnewsvia finnhub
Resmed completes $340M Noctrix takeover
The buyout gives Resmed control of a noninvasive treatment for restless legs syndrome.
?Jun 1, 6:03 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ResMed (RMD) is a high-quality medical device company with a dominant position in sleep apnea and respiratory care, a strong recurring revenue base from device consumables and cloud-connected software, and historically solid free cash flow generation. The 18.7% drawdown from the 30-day high occurs in a news vacuum — no recent headlines or SEC filings are available to explain the drop, which suggests the move may be driven by sector rotation, broader market risk-off, or GLP-1 obesity drug overhang fears (a recurring narrative for RMD) rather than company-specific deterioration. The macro backdrop shows a T10Y3M spread elevated at +0.76 (1.6σ above trend), which modestly pressures growth/healthcare multiples but is not specifically damaging to RMD's defensive recurring-revenue model.
?Jun 1, 6:03 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $2.27 cash available; close=$186.48.
❖Jun 1, 4:05 PMnewsvia finnhub
Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS).SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has completed its acquisition of Noctrix Health, Inc., a medical device company developing clinically validated wearable t
?Jun 1, 10:10 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
RMD is down ~1.85% today with no attributable headline catalyst, suggesting this is technically or flow-driven selling rather than event-driven. The move is below the 2-5% threshold that would indicate strong institutional conviction, so this is a moderate momentum signal. Macro context (T10Y3M at +1.6σ above trend) is mildly risk-off for growth/healthcare names but is not a strong direct tailwind for further selling in RMD specifically. With 335 minutes remaining (essentially a full session still ahead), there is ample time for the move to continue or reverse. In the absence of a clear reversal pattern or fade signal, and given the system's bounded risk framework, the default lean is slight continuation. However, the sub-2% move and lack of news keep conviction modest — this is a borderline read with no strong reason to fade but no strong catalyst to accelerate selling either.
?Jun 1, 7:03 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $29.62 cash available; close=$190.57.
✓May 29, 6:03 PMdecisionacted
Agent 8 — Dip Buyer (Peer-Aware) — decide: buy
ResMed (RMD) is a fundamentally sound medical device leader in sleep apnea and respiratory care with a strong recurring revenue base, healthy margins, and a history of recovering from sector-driven drawdowns. The 17.2% drop appears macro/sector-driven rather than company-specific — there are no negative earnings reports, guidance cuts, or insider sales to explain the move. The Health Care sector is underperforming SPY over both 5d and 30d, suggesting RMD is being dragged down by a sector-wide rotation rather than idiosyncratic deterioration. VIX at the 19th percentile indicates low fear, a benign environment for mean-reversion trades, and the yield curve is positively sloped (+46bps 2s10s), which is not structurally hostile for healthcare.
✓May 29, 6:03 PMdecisionacted
Agent 6 — Options Momentum — decide: buy
PUT on RMD — 5-day return -8.81% with close below 20-day MA ($205.09). IV 34.9%. Sized 1 contract(s) at $7.51 premium.
❖May 29, 3:05 PMnewsvia finnhub
Friday's session: top gainers and losers in the S&P500 index
Let's have a look at the top S&P500 gainers and losers one hour before the close of the markets of today's session.
?May 29, 10:45 AMdecisionconsidered
Agent 7 — Day Trader — decide: skip
RMD is down 1.72% today, which is a moderate but not extreme intraday move. There are no recent headlines to explain the move, suggesting it may be flow-driven or sympathy selling rather than a fundamental catalyst. The macro context shows the 10Y-3M spread elevated at +1.8σ above trend — this is a steepening yield curve signal that tends to pressure growth/defensive healthcare names like RMD modestly, but RMD is not directly in the 'Banks' or 'Recession-sensitive' bucket where this signal is most reactive. With 300 minutes remaining (essentially a full afternoon session), there is ample time for either continuation or reversal. The move at -1.72% is below the 2% threshold where momentum becomes particularly self-reinforcing. Without a clear catalyst or confirmed volume surge, and given that no news is driving the narrative, the setup is marginally below the 0.5 continuation threshold. The lack of news cuts both ways, but the steepening curve context does not provide a strong tailwind for further downside in RMD specifically. Leaning just below the trigger on the basis that the move lacks a clear driver and reversal risk into the close is roughly equal to continuation risk.
?May 29, 7:02 AMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $3.04 cash available; close=$203.42.
?May 29, 7:01 AMdecisionconsidered
Agent 8 — Dip Buyer (Peer-Aware) — decide: skip_no_cash
Wanted to buy but only $9.19 cash available; close=$203.42.
▢May 28, 8:00 PMjournal
Agent 6 — Options Momentum opened long 100 @ $7.51
?May 28, 6:01 PMdecisionconsidered
Agent 5 — Dip Buyer (Evolving) — decide: skip_no_cash
Wanted to buy but only $12.25 cash available; close=$206.10.
?May 28, 6:01 PMdecisionconsidered
Agent 4 — Dip Buyer (Frozen) — decide: skip
ResMed (RMD) is a fundamentally strong medical device company with a dominant position in sleep apnea treatment and a growing software/services business, and the 13.1% drop from its 30-day high does not appear tied to any company-specific deterioration given the absence of negative news or recent SEC filings flagging issues. The macro context, however, is a headwind: 10-year inflation expectations (T10YIE) are running 2.4σ above their 24-month trend, which pressures long-duration, growth-oriented healthcare names like RMD through higher discount rates. Without a clear catalyst for recovery in the near term and with elevated rate expectations potentially persisting, the path back to $234.91 within 90 days is uncertain despite the company's solid underlying business.
❖May 28, 5:40 AMnewsvia finnhub
ResMed Inc (NYSE:RMD): A Top Dividend Stock with Strong Profitability and Financial Health
ResMed (RMD) offers a safe, growing dividend backed by strong profitability and financial health. With a 7/10 dividend rating, 22% payout ratio, and top-tier earnings quality, it exemplifies a sustainable income strategy.

← Back to dashboard